Federal Court Orders DEA To Explain Marijuana Research Block
A federal court is ordering the Drug Enforcement Administration (DEA) to respond to a lawsuit concerning the status of applications for research-grade marijuana manufacturers.
Researchers filed a suit against the agency last month, arguing that the quality of cannabis supplied from the nation’s only federally authorized cultivation facility is inadequate and that additional manufacturers are necessary to increase the diversity of marijuana for research purposes.
DEA said in 2016 that it was accepting applications for such facilities but has so far declined to act on the dozens it has received. The Scottsdale Research Institute (SRI), which submitted an application to grow its own cannabis in order to conduct clinical trials on marijuana’s potential to treat symptoms of post-traumatic stress disorder, is seeking a resolution through the courts.
On Monday, the U.S. Court of Appeals for the D.C. Circuit handed SRI an initial procedural victory, issuing an order that DEA “file a response to the amended mandamus petition, not to exceed 7,800 words, within 30 days of the date of this order.”